Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67


Rheology of mixed solutions of sulfonated methyl esters and betaine in relation to the growth of giant micelles and shampoo applications.

Yavrukova VI, Radulova GM, Danov KD, Kralchevsky PA, Xu H, Ung YW, Petkov JT.

Adv Colloid Interface Sci. 2019 Nov 7:102062. doi: 10.1016/j.cis.2019.102062. [Epub ahead of print] Review.


Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter.

Thompson R, Cheung P, Chu W, Myrehaug S, Poon I, Sahgal A, Soliman H, Tseng CL, Wong S, Ung Y, Beatriz Kinupe Abrah√£o A, Erler D, Zhang L, Ko YJ, Chung HT.

Radiother Oncol. 2019 Sep 19. pii: S0167-8140(19)33064-6. doi: 10.1016/j.radonc.2019.08.018. [Epub ahead of print]


Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review.

Swaminath A, Vella ET, Ramchandar K, Robinson A, Simone C, Sun A, Ung YC, Yasufuku K, Ellis PM.

Curr Oncol. 2019 Jun;26(3):e398-e404. doi: 10.3747/co.26.4549. Epub 2019 Jun 1. Review.


Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.

Sun A, Durocher-Allen LD, Ellis PM, Ung YC, Goffin JR, Ramchandar K, Darling G.

Curr Oncol. 2019 Jun;26(3):e372-e384. doi: 10.3747/co.26.4481. Epub 2019 Jun 1. Review.


How equitable is access to treatment for lung cancer patients? A population-based review of treatment practices in Ontario.

Evans WK, Stiff J, Woltman KJ, Ung YC, Su-Myat S, Manivong P, Tsang K, Nazen-Rad N, Gatto A, Tyrrell A, Anas R, Darling G, Sawka C.

Lung Cancer Manag. 2017 Dec;6(3):77-86. doi: 10.2217/lmt-2017-0013. Epub 2017 Dec 1.


Properties of the micelles of sulfonated methyl esters determined from the stepwise thinning of foam films and by rheological measurements.

Basheva ES, Danov KD, Radulova GM, Kralchevsky PA, Xu H, Ung YW, Petkov JT.

J Colloid Interface Sci. 2019 Mar 7;538:660-670. doi: 10.1016/j.jcis.2018.12.034. Epub 2018 Dec 11.


Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity.

Lim SYM, Binti Azidin AR, Ung YT, Al-Shagga M, Alshawsh MA, Mohamed Z, Ong CE, Pan Y.

Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):423-431. doi: 10.1007/s13318-018-0518-2.


Current High-Throughput Approaches of Screening Modulatory Effects of Xenobiotics on Cytochrome P450 (CYP) Enzymes.

Ung YT, Ong CE, Pan Y.

High Throughput. 2018 Sep 29;7(4). pii: E29. doi: 10.3390/ht7040029. Review.


Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?

Merino Lara T, Helou J, Poon I, Sahgal A, Chung HT, Chu W, Soliman H, Ung Y, Verma S, Cheema P, Cheng S, Khanna S, Erler D, Zhang L, Cheung P.

Lung Cancer. 2018 Oct;124:219-226. doi: 10.1016/j.lungcan.2018.08.005. Epub 2018 Aug 7.


Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.

Sun A, Durocher-Allen LD, Ellis PM, Ung YC, Goffin JR, Ramchandar K, Darling G.

Clin Oncol (R Coll Radiol). 2018 Oct;30(10):658-666. doi: 10.1016/j.clon.2018.06.008. Epub 2018 Jul 11.


Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M.

J Clin Oncol. 2017 Sep 1;35(25):2960-2974. doi: 10.1200/JCO.2017.72.4401. Epub 2017 Apr 24. Review.


Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.

Ellis PM, Vella ET, Ung YC.

Clin Lung Cancer. 2017 Sep;18(5):444-459.e1. doi: 10.1016/j.cllc.2017.02.001. Epub 2017 Feb 16. Review.


Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer.

Falkson CB, Vella ET, Yu E, El-Mallah M, Mackenzie R, Ellis PM, Ung YC.

Curr Oncol. 2017 Feb;24(1):e44-e49. doi: 10.3747/co.24.3358. Epub 2017 Feb 27.


Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review.

Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis PM.

Clin Lung Cancer. 2017 May;18(3):259-273.e8. doi: 10.1016/j.cllc.2016.07.002. Epub 2016 Jul 12. Review.


Radiotherapy With Curative Intent in Patients With Early-stage, Medically Inoperable, Non-Small-cell Lung Cancer: A Systematic Review.

Falkson CB, Vella ET, Yu E, El-Mallah M, Mackenzie R, Ellis PM, Ung YC.

Clin Lung Cancer. 2017 Mar;18(2):105-121.e5. doi: 10.1016/j.cllc.2016.10.008. Epub 2016 Oct 27. Review.


The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review.

Kulkarni S, Vella ET, Coakley N, Cheng S, Gregg R, Ung YC, Ellis PM.

J Thorac Oncol. 2016 Jul;11(7):989-1002. doi: 10.1016/j.jtho.2016.03.007. Epub 2016 Mar 21. Review.


A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non-Small-Cell Lung Cancer.

Swaminath A, Wright JR, Tsakiridis TK, Ung YC, Pond GR, Sur R, Corbett TB, Okawara G, Levine MN.

Clin Lung Cancer. 2016 Mar;17(2):142-9. doi: 10.1016/j.cllc.2015.09.008. Epub 2015 Oct 9.


Systematic review of guidelines for the management of suspected lung cancer in primary care.

Del Giudice ME, Young SM, Vella ET, Ash M, Bansal P, Robinson A, Skrastins R, Ung Y, Zeldin R, Levitt C.

Can Fam Physician. 2014 Aug;60(8):e395-404. Review.


Guideline for referral of patients with suspected lung cancer by family physicians and other primary care providers.

Del Giudice ME, Young SM, Vella ET, Ash M, Bansal P, Robinson A, Skrastins R, Ung Y, Zeldin R, Levitt C.

Can Fam Physician. 2014 Aug;60(8):711-6, e376-82. Review. English, French.


Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25.

Cheung P, Faria S, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamed I, Wright JR, Hollenhorst H, de Metz C, Campbell H, Vu TT, Karvat A, Wai ES, Ung YC, Goss G, Shepherd FA, O'Brien P, Ding K, O'Callaghan C.

J Natl Cancer Inst. 2014 Jul 29;106(8). pii: dju164. doi: 10.1093/jnci/dju164. Print 2014 Aug. Erratum in: J Natl Cancer Inst. 2015 Jan;107(1): dju430 doi:10.1093/jnci/dju430.


A mixed methods approach to understand variation in lung cancer practice and the role of guidelines.

Brouwers MC, Makarski J, Garcia K, Akram S, Darling GE, Ellis PM, Evans WK, Giacomini M, Martelli-Reid L, Ung YC.

Implement Sci. 2014 Mar 22;9(1):36. doi: 10.1186/1748-5908-9-36.


Screening high-risk populations for lung cancer: guideline recommendations.

Roberts H, Walker-Dilks C, Sivjee K, Ung Y, Yasufuku K, Hey A, Lewis N; Lung Cancer Screening Guideline Development Group.

J Thorac Oncol. 2013 Oct;8(10):1232-7. doi: 10.1097/JTO.0b013e31829fd3d5.


Morphological and biochemical responses of Oryza sativa L. (cultivar MR219) to ion beam irradiation.

Ling AP, Ung YC, Hussein S, Harun AR, Tanaka A, Yoshihiro H.

J Zhejiang Univ Sci B. 2013 Dec;14(12):1132-43. doi: 10.1631/jzus.B1200126.


Improving the quality of lung cancer care in Ontario: the lung cancer disease pathway initiative.

Evans WK, Ung YC, Assouad N, Chyjek A, Sawka C.

J Thorac Oncol. 2013 Jul;8(7):876-82. doi: 10.1097/JTO.0b013e31828cb548.


Automatic Segmentation of Lung Carcinoma Using 3D Texture Features in 18-FDG PET/CT.

Markel D, Caldwell C, Alasti H, Soliman H, Ung Y, Lee J, Sun A.

Int J Mol Imaging. 2013;2013:980769. doi: 10.1155/2013/980769. Epub 2013 Feb 26.


Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience.

Cukier M, Smith AJ, Milot L, Chu W, Chung H, Fenech D, Herschorn S, Ko Y, Rowsell C, Soliman H, Ung YC, Wong CS.

Eur J Surg Oncol. 2012 Aug;38(8):677-82. doi: 10.1016/j.ejso.2012.05.001. Epub 2012 May 24.


Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.

Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D.

J Thorac Oncol. 2012 Mar;7(3):579-86. doi: 10.1097/JTO.0b013e31823f459c.


Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.

Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Gu CS, Kuruvilla MS, Cline KJ, Julian JA, Evans WK, Levine MN.

J Thorac Oncol. 2011 Aug;6(8):1367-72. doi: 10.1097/JTO.0b013e318220c912. Erratum in: J Thorac Oncol. 2012 Mar;7(3):628.


Autocontouring and manual contouring: which is the better method for target delineation using 18F-FDG PET/CT in non-small cell lung cancer?

Wu K, Ung YC, Hwang D, Tsao MS, Darling G, Maziak DE, Tirona R, Mah K, Wong CS.

J Nucl Med. 2010 Oct;51(10):1517-23. doi: 10.2967/jnumed.110.077974. Epub 2010 Sep 16.


Accelerated hypofractionated radiotherapy for early-stage non-small-cell lung cancer: long-term results.

Soliman H, Cheung P, Yeung L, Poon I, Balogh J, Barbera L, Spayne J, Danjoux C, Dahele M, Ung Y.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):459-65. doi: 10.1016/j.ijrobp.2009.11.003. Epub 2010 Apr 10.


First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.

Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

J Thorac Oncol. 2010 Feb;5(2):260-74. doi: 10.1097/JTO.0b013e3181c6f035. Review.


Adjuvant radiotherapy for gastric cancer: A dosimetric comparison of 3-dimensional conformal radiotherapy, tomotherapy and conventional intensity modulated radiotherapy treatment plans.

Dahele M, Skinner M, Schultz B, Cardoso M, Bell C, Ung YC.

Med Dosim. 2010 Summer;35(2):115-21. doi: 10.1016/j.meddos.2009.03.003. Epub 2009 Apr 15.


PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings?

Wu K, Ung YC, Hornby J, Freeman M, Hwang D, Tsao MS, Dahele M, Darling G, Maziak DE, Tirona R, Mah K, Wong CS.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):699-706. doi: 10.1016/j.ijrobp.2009.05.028. Epub 2009 Oct 14.


Positron emission tomography in staging early lung cancer: a randomized trial.

Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Miller JD, Gu CS, Cline KJ, Evans WK, Levine MN.

Ann Intern Med. 2009 Aug 18;151(4):221-8, W-48. Epub 2009 Jul 6.


The management of thymoma: a systematic review and practice guideline.

Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, Yu E, Smith CA, McNair S, Ung YC, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

J Thorac Oncol. 2009 Jul;4(7):911-9. Review.


The role of positron emission tomography in the management of non-small cell lung cancer.

Behzadi A, Ung Y, Lowe V, Deschamps C.

Can J Surg. 2009 Jun;52(3):235-42. Review.


18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.

Dahele M, Ung YC, Ehrlich L, Silverberg J, Balogh J, Wong CS.

J Otolaryngol Head Neck Surg. 2008 Oct;37(5):712-7.


Developing a methodology for three-dimensional correlation of PET-CT images and whole-mount histopathology in non-small-cell lung cancer.

Dahele M, Hwang D, Peressotti C, Sun L, Kusano M, Okhai S, Darling G, Yaffe M, Caldwell C, Mah K, Hornby J, Ehrlich L, Raphael S, Tsao M, Behzadi A, Weigensberg C, Ung YC.

Curr Oncol. 2008 Oct;15(5):62-9.


Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Vesprini D, Ung Y, Dinniwell R, Breen S, Cheung F, Grabarz D, Kamra J, Mah K, Mansouri A, Pond G, Brock K, Darling G, Knox J, Haider M, Wong RK.

Clin Oncol (R Coll Radiol). 2008 Oct;20(8):631-8. doi: 10.1016/j.clon.2008.06.004. Epub 2008 Aug 27.


Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR.

J Clin Oncol. 2008 May 20;26(15):2450-6. doi: 10.1200/JCO.2007.14.4824. Epub 2008 Mar 31.


A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus.

Kassam Z, Wong RK, Ringash J, Ung Y, Kamra J, DeBoer G, O'Brien M, Kim J, Loblaw DA, Wong S, Cummings B, Davey P.

Clin Oncol (R Coll Radiol). 2008 Feb;20(1):53-60.


Integrating regional and community lung cancer services to improve patient care.

Dahele M, Ung Y, Meharchand J, Shulman H, Zeldin R, Behzadi A, Simone C, Cheng S, Weigensberg C, Sivjee K.

Curr Oncol. 2007 Dec;14(6):234-7.


18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.

Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

J Natl Cancer Inst. 2007 Dec 5;99(23):1753-67. Epub 2007 Nov 27. Review.


Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis.

Lo DS, Zeldin RA, Skrastins R, Fraser IM, Newman H, Monavvari A, Ung YC, Joseph H, Downton T, Maxwell L, Meharchand J.

J Thorac Oncol. 2007 Nov;2(11):1001-6.


Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.

Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, Strawn JR, Ung YC, Shepherd FA; Cancer Care Ontario; American Society of Clinical Oncology.

J Clin Oncol. 2007 Dec 1;25(34):5506-18. Epub 2007 Oct 22.


Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.

Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F; National Cancer Institute of Canada Clinical Trials Group Study BR.20.

J Clin Oncol. 2007 Sep 20;25(27):4278-84.


18F-FDG PET in planning radiation treatment of non-small cell lung cancer: where exactly is the tumor?

Dahele MR, Ung YC.

J Nucl Med. 2007 Aug;48(8):1402; author reply 1403. No abstract available.


Management of unresected stage III non-small cell lung cancer: a systematic review.

Okawara G, Mackay JA, Evans WK, Ung YC; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

J Thorac Oncol. 2006 May;1(4):377-93. Review.


Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN.

J Clin Oncol. 2007 Mar 20;25(9):1027-32. Epub 2007 Feb 20.


Supplemental Content

Support Center